The T classification of clinically localized prostate cancer. An appraisal based on disease outcome after radiation therapy
- 1 April 1994
- Vol. 73 (7) , 1904-1912
- https://doi.org/10.1002/1097-0142(19940401)73:7<1904::aid-cncr2820730722>3.0.co;2-6
Abstract
No abstract availableKeywords
This publication has 30 references indexed in Scilit:
- Prostate-specific antigen. An important marker for prostate cancer treated by external beam radiation therapyCancer, 1993
- The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate CancerJournal of Urology, 1993
- Ability of preoperative serum prostatespecific antigen value to predict pathologic stage and DNA ploidy Influence of clinical stage and tumor gradeUrology, 1993
- Clinical stage Bo or T1c prostate cancer: Nonpalpable disease identified by elevated serum prostate-specific antigen concentrationUrology, 1993
- Prostate-specific antigen as a prognostic factor for prostate cancer treated by external beam radiotherapyInternational Journal of Radiation Oncology*Biology*Physics, 1992
- The TNM classification of prostate cancerThe Prostate, 1992
- Prostate-Specific Antigen and External Beam Radiation Therapy in Prostate CancerCancer, 1991
- New Staging Systems for Prostate CancerJournal of Urology, 1989
- TNM-AtlasPublished by Springer Nature ,1982
- Hormone therapy in prostatic cancerThe American Journal of Medicine, 1956